Hims & Hers Health (HIMS) Total Non-Current Liabilities (2020 - 2026)
Hims & Hers Health (HIMS) reported Total Non-Current Liabilities of $1.8 billion for Q1 2026, up 431.74% on a YoY basis from $340.0 million in Q1 2025, and up 12.85% sequentially from $1.6 billion in Q4 2025.
Hims & Hers Health (HIMS) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Hims & Hers Health (HIMS) has 7 years of Total Non-Current Liabilities data on file, last reported at $1.8 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 431.74% year-over-year to $1.8 billion; the trailing twelve-month figure through Mar 2026 stood at $1.8 billion (up 431.74% YoY), and the FY2025 full-year result was $1.6 billion, up 594.06% from the prior year.
- Total Non-Current Liabilities climbed to $1.8 billion in Q1 2026, from $1.6 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.8 billion in Q1 2026 to a low of $53.8 million in Q1 2022.
- A 5-year average of $463.6 million and a median of $103.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities plunged 36.06% in 2022 and jumped 1008.31% in 2025, its largest moves.
- Tracing HIMS's Total Non-Current Liabilities over 5 years: stood at $54.6 million in 2022, then surged by 78.02% to $97.1 million in 2023, then soared by 137.63% to $230.8 million in 2024, then soared by 594.06% to $1.6 billion in 2025, then advanced by 12.85% to $1.8 billion in 2026.
- Business Quant data shows HIMS's Total Non-Current Liabilities at $1.8 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 599.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 1.86 Mn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | 1.81 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.81 Bn |
| Dec 31, 2025 | 1.60 Bn |
| Sep 30, 2025 | 1.65 Bn |
| Jun 30, 2025 | 1.31 Bn |
| Mar 31, 2025 | 340.01 Mn |
| Dec 31, 2024 | 230.82 Mn |
| Sep 30, 2024 | 162.21 Mn |
| Jun 30, 2024 | 118.51 Mn |
| Mar 31, 2024 | 103.60 Mn |
| Dec 31, 2023 | 97.14 Mn |
| Sep 30, 2023 | 85.30 Mn |
| Jun 30, 2023 | 69.81 Mn |
| Mar 31, 2023 | 63.48 Mn |
| Dec 31, 2022 | 54.57 Mn |
| Sep 30, 2022 | 71.63 Mn |
| Jun 30, 2022 | 60.54 Mn |
| Mar 31, 2022 | 53.81 Mn |
| Dec 31, 2021 | 85.34 Mn |
| Sep 30, 2021 | 53.72 Mn |
| Jun 30, 2021 | 52.75 Mn |